United Therapeutics Corp
NASDAQ:UTHR
United Therapeutics Corp
Income from Continuing Operations
United Therapeutics Corp
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
United Therapeutics Corp
NASDAQ:UTHR
|
Income from Continuing Operations
$1.1B
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
15%
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$456m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is United Therapeutics Corp's Income from Continuing Operations?
Income from Continuing Operations
1.1B
USD
Based on the financial report for Mar 31, 2024, United Therapeutics Corp's Income from Continuing Operations amounts to 1.1B USD.
What is United Therapeutics Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
15%
Over the last year, the Income from Continuing Operations growth was 44%. The average annual Income from Continuing Operations growth rates for United Therapeutics Corp have been 37% over the past three years , and 15% over the past ten years .